CHMP backs Boehringer’s Spevigo for preventing rare psoriasis flare-ups
The CHMP recommendation is based on positive results from the Phase IIb EFFISAYIL 2 trial which enrolled 123 patients.
The CHMP recommendation is based on positive results from the Phase IIb EFFISAYIL 2 trial which enrolled 123 patients.
What's Your Reaction?
